Kardigan, Inc. (KARD)
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Kardigan, Inc.
NASDAQ:KARDHealthcare · Biotechnology
+0.47%$12.80
AH Close$12.80+0.00%vs close
AH Close$12.80+0.00%vs close
Mkt Cap$1.2B
Float38.46M
O/S93.5M
Inst Own61.2%
SI11.6%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$191.94M
Total Assets$390.94M
Free Cash Flow-$157.7M
Debt & Equity
Total Debt$13.83M
Total Equity-$250.34M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in KARD's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$390.94M
Liabilities$641.28M
Accounts Receivable$0
Accounts Payable$7.99M
Inventory$0
PP&E (Net)$18.23M
Goodwill$0
Intangible Assets$23.23M
Income Statement
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Revenue | $0 |
| YoY Growth | - |
| Cost of Revenue | $0 |
| Gross Profit | $0 |
| Gross Margin | - |
| Research and Development | $153.09M |
| Selling, General, and Administrative | $48.75M |
| Other | $0 |
| Total Operating Expenses | $201.84M |
| Operating Income (EBIT) | -$201.84M |
| Operating Margin | - |
| Interest Expense | $0 |
| Interest Income | $6.85M |
| Other Income (Expense) | $5.38M |
| Income Before Tax (EBT) | -$196.45M |
| Income Tax Expense | -$4.51M |
| Net Income | -$191.94M |
| Net Income Margin | - |
| Supplementary Data | |
| EPS | -3.20 |
| Diluted EPS | -3.20 |
| Weighted Average OS | 59.96M |
| EBITDA | -$195.99M |
| EBITDA Margin | - |
Balance Sheet
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Assets | |
| Current Assets | |
| Cash and Cash Equivalents | $108.99M |
| Short-Term Investments | $226.5M |
| Cash and Short-Term Investments | $335.49M |
| Accounts Receivable | $0 |
| Inventory | $0 |
| Other Current Assets | $9.87M |
| Total Current Assets | $345.35M |
| Long-Term Assets | |
| Property, Plant & Equipment Net | $18.23M |
| Goodwill | $0 |
| Intangible Assets | $23.23M |
| Long-Term Investments | $0 |
| Deferred Tax Assets | $0 |
| Other Long-Term Assets | $4.13M |
| Total Long-Term Assets | $45.59M |
| Other Assets | $0 |
| Total Assets | $390.94M |
| Liabilities | |
| Current Liabilities | |
| Accounts Payable | $7.99M |
| Short-Term Debt | $0 |
| Current Income Tax Payable | $0 |
| Current Unearned Revenue | $0 |
| Other Current Liabilities | $14.89M |
| Total Current Liabilities | $37.54M |
| Long-Term Liabilities | |
| Long-Term Debt | $0 |
| Long-Term Unearned Revenue | $0 |
| Long-Term Deferred Tax Liabilities | $0 |
| Other Long-Term Liabilities | $593.05M |
| Total Long-Term Liabilities | $603.74M |
| Other Liabilities | $0 |
| Total Liabilities | $641.28M |
| Stockholders' Equity | |
| Preferred Stock | $0 |
| Common Stock | $0 |
| Retained Earnings | -$281.09M |
| Comprehensive Income & Other | $63K |
| Other Stockholders' Equity | $30.75M |
| Total Equity | -$250.34M |
| Minority Interest | $0 |
| Total Liabilities and Equity | $390.94M |
| Supplementary Data | |
| Total Debt | $13.83M |
| Net Debt | -$95.16M |
Cash Flow Statement
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Operating Activities | |
| Net Income | -$191.94M |
| Depreciation & Amortization | $5.85M |
| Deferred Income Tax | -$4.51M |
| Stock-Based Compensation | $15.85M |
| Changes in Working Capital: | |
| Accounts Receivable | $0 |
| Inventory | $0 |
| Accounts Payable | $1.76M |
| Other Working Capital | $4.67M |
| Total Working Capital Change | $6.43M |
| Other Non-Cash Items | $17.27M |
| Net Cash from Operating | -$151.06M |
| Investing Activities | |
| Capital Expenditures | -$5.08M |
| Acquisitions | -$3.96M |
| Purchases of Investments | -$243.44M |
| Sales of Investments | $17M |
| Other Investing Activities | -$1.56M |
| Net Cash from Investing | -$237.04M |
| Financing Activities | |
| Debt Repaid | - |
| Common Stock Issuance | $561K |
| Common Stock Repurchases | $0 |
| Dividends Paid | $0 |
| Other Financing Activities | -$6.36M |
| Net Cash from Financing | $447.81M |
| Forex Effect | $0 |
| Net Change in Cash | $59.71M |
| Supplementary Data | |
| Operating Cash Flow | -$151.06M |
| Capital Expenditure | -$6.64M |
| Free Cash Flow | -$157.7M |
| Cash at Beginning | $49.81M |
| Cash at End | $109.53M |